Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience
Chronic urticaria is a condition characterized by the appearance of wheals and/or angioedema that last for at least 6 weeks. According to the recent recommendations, if H1-antihistamines used in four times licensed doses remain ineffective, add-on treatment with omalizumab, cyclosporine A or montelu...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Termedia Publishing House
2016-02-01
|
Series: | Przegląd Dermatologiczny |
Subjects: | |
Online Access: | https://www.termedia.pl/Omalizumab-in-the-treatment-of-chronic-spontaneous-urticaria-literature-review-and-own-experience,56,26911,1,1.html |
id |
doaj-67ca052961124729aa00e83d8fb37325 |
---|---|
record_format |
Article |
spelling |
doaj-67ca052961124729aa00e83d8fb373252020-11-24T23:15:50ZengTermedia Publishing HousePrzegląd Dermatologiczny0033-25262084-98932016-02-011031647010.5114/dr.2016.5774726911Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experienceJoanna DawickaAleksandra WilkowskaElżbieta Grubska-SuchanekRoman NowickiChronic urticaria is a condition characterized by the appearance of wheals and/or angioedema that last for at least 6 weeks. According to the recent recommendations, if H1-antihistamines used in four times licensed doses remain ineffective, add-on treatment with omalizumab, cyclosporine A or montelukast should be applied. This paper offers a literature review of the studies on using omalizumab in chronic spontaneous urticaria (CSU) treatment. Moreover, it presents our own experience with the use of omalizumab in the treatment of two patients with CSU. Both patients were treated with H1-antihistamines in four times licensed doses recommended by European guidelines, oral corticosteroids, montelukast, and methotrexate – all without satisfactory results. During the time of the omalizumab therapy both patients achieved a significant improvement measured by the decrease in the Average Urticaria Activity Score for 7 days (UAS7) – the first patient from 34 to 11.8 points, the second one from 41 to 5.76.https://www.termedia.pl/Omalizumab-in-the-treatment-of-chronic-spontaneous-urticaria-literature-review-and-own-experience,56,26911,1,1.htmlurticaria omalizumab chronic spontaneous urticaria anti-IgE antibodies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Joanna Dawicka Aleksandra Wilkowska Elżbieta Grubska-Suchanek Roman Nowicki |
spellingShingle |
Joanna Dawicka Aleksandra Wilkowska Elżbieta Grubska-Suchanek Roman Nowicki Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience Przegląd Dermatologiczny urticaria omalizumab chronic spontaneous urticaria anti-IgE antibodies |
author_facet |
Joanna Dawicka Aleksandra Wilkowska Elżbieta Grubska-Suchanek Roman Nowicki |
author_sort |
Joanna Dawicka |
title |
Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience |
title_short |
Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience |
title_full |
Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience |
title_fullStr |
Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience |
title_full_unstemmed |
Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience |
title_sort |
omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience |
publisher |
Termedia Publishing House |
series |
Przegląd Dermatologiczny |
issn |
0033-2526 2084-9893 |
publishDate |
2016-02-01 |
description |
Chronic urticaria is a condition characterized by the appearance of wheals and/or angioedema that last for at least 6 weeks. According to the recent recommendations, if H1-antihistamines used in four times licensed doses remain ineffective, add-on treatment with omalizumab, cyclosporine A or montelukast should be applied. This paper offers a literature review of the studies on using omalizumab in chronic spontaneous urticaria (CSU) treatment. Moreover, it presents our own experience with the use of omalizumab in the treatment of two patients with CSU. Both patients were treated with H1-antihistamines in four times licensed doses recommended by European guidelines, oral corticosteroids, montelukast, and methotrexate – all without satisfactory results. During the time of the omalizumab therapy both patients achieved a significant improvement measured by the decrease in the Average Urticaria Activity Score for 7 days (UAS7) – the first patient from 34 to 11.8 points, the second one from 41 to 5.76. |
topic |
urticaria omalizumab chronic spontaneous urticaria anti-IgE antibodies |
url |
https://www.termedia.pl/Omalizumab-in-the-treatment-of-chronic-spontaneous-urticaria-literature-review-and-own-experience,56,26911,1,1.html |
work_keys_str_mv |
AT joannadawicka omalizumabinthetreatmentofchronicspontaneousurticarialiteraturereviewandownexperience AT aleksandrawilkowska omalizumabinthetreatmentofchronicspontaneousurticarialiteraturereviewandownexperience AT elzbietagrubskasuchanek omalizumabinthetreatmentofchronicspontaneousurticarialiteraturereviewandownexperience AT romannowicki omalizumabinthetreatmentofchronicspontaneousurticarialiteraturereviewandownexperience |
_version_ |
1725589376130351104 |